CA2233278A1 - Stimulation of cell-mediated immune responses by targeted particulate genetic immunization - Google Patents
Stimulation of cell-mediated immune responses by targeted particulate genetic immunization Download PDFInfo
- Publication number
- CA2233278A1 CA2233278A1 CA002233278A CA2233278A CA2233278A1 CA 2233278 A1 CA2233278 A1 CA 2233278A1 CA 002233278 A CA002233278 A CA 002233278A CA 2233278 A CA2233278 A CA 2233278A CA 2233278 A1 CA2233278 A1 CA 2233278A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- tumor rejection
- host
- particulate
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002068 genetic effect Effects 0.000 title claims abstract description 40
- 230000003053 immunization Effects 0.000 title claims abstract description 16
- 238000002649 immunization Methods 0.000 title claims abstract description 16
- 230000000638 stimulation Effects 0.000 title description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 173
- 108091007433 antigens Proteins 0.000 claims abstract description 165
- 102000036639 antigens Human genes 0.000 claims abstract description 160
- 239000000427 antigen Substances 0.000 claims abstract description 159
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 101
- 239000002157 polynucleotide Substances 0.000 claims abstract description 101
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 65
- 230000000890 antigenic effect Effects 0.000 claims abstract description 47
- 239000012634 fragment Substances 0.000 claims abstract description 43
- 241000282414 Homo sapiens Species 0.000 claims abstract description 38
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 13
- 238000002347 injection Methods 0.000 claims description 94
- 239000007924 injection Substances 0.000 claims description 94
- 206010028980 Neoplasm Diseases 0.000 claims description 90
- 230000037361 pathway Effects 0.000 claims description 57
- 108020004414 DNA Proteins 0.000 claims description 56
- 102000043129 MHC class I family Human genes 0.000 claims description 40
- 108091054437 MHC class I family Proteins 0.000 claims description 40
- 230000003612 virological effect Effects 0.000 claims description 29
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 24
- 238000001727 in vivo Methods 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 14
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 238000010254 subcutaneous injection Methods 0.000 claims description 9
- 239000007929 subcutaneous injection Substances 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 7
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 6
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 6
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 238000012737 microarray-based gene expression Methods 0.000 claims description 5
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000011931 Nucleoproteins Human genes 0.000 claims 4
- 108010061100 Nucleoproteins Proteins 0.000 claims 4
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 230000030741 antigen processing and presentation Effects 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract description 17
- 230000036039 immunity Effects 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 51
- 108010058846 Ovalbumin Proteins 0.000 description 45
- 229940092253 ovalbumin Drugs 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 25
- 239000011324 bead Substances 0.000 description 18
- 230000006698 induction Effects 0.000 description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 14
- 239000010931 gold Substances 0.000 description 14
- 229910052737 gold Inorganic materials 0.000 description 14
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 210000000170 cell membrane Anatomy 0.000 description 11
- 230000002500 effect on skin Effects 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 241001529936 Murinae Species 0.000 description 10
- 238000010253 intravenous injection Methods 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 210000000172 cytosol Anatomy 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000032258 transport Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 101150066555 lacZ gene Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 210000000712 G cell Anatomy 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 210000003595 dermal dendritic cell Anatomy 0.000 description 2
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 2
- -1 gplOO Proteins 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 101150110188 30 gene Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101150020229 Apcs gene Proteins 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100452236 Caenorhabditis elegans inf-1 gene Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 101150023426 Ccin gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 101100390736 Danio rerio fign gene Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101100207408 Homo sapiens TRA gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 101100390738 Mus musculus Fign gene Proteins 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000312117 Phago Species 0.000 description 1
- 235000014548 Rubus moluccanus Nutrition 0.000 description 1
- 101150115433 SLC26A5 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53555695A | 1995-09-28 | 1995-09-28 | |
| US08/535,556 | 1995-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2233278A1 true CA2233278A1 (en) | 1997-04-03 |
Family
ID=24134735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002233278A Abandoned CA2233278A1 (en) | 1995-09-28 | 1996-09-27 | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0863704A4 (ko) |
| JP (1) | JPH11512724A (ko) |
| KR (1) | KR19990063672A (ko) |
| CN (1) | CN1201369A (ko) |
| AU (1) | AU716497B2 (ko) |
| BG (1) | BG102355A (ko) |
| CA (1) | CA2233278A1 (ko) |
| CZ (1) | CZ92998A3 (ko) |
| HU (1) | HUP9802651A3 (ko) |
| NO (1) | NO981386L (ko) |
| NZ (1) | NZ319891A (ko) |
| PL (1) | PL325953A1 (ko) |
| SK (1) | SK40198A3 (ko) |
| TR (1) | TR199800573T2 (ko) |
| WO (1) | WO1997011605A1 (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3210997A (en) * | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
| TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6287569B1 (en) * | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
| WO1999041369A2 (en) * | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Genetic vaccine vector engineering |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| NZ515041A (en) * | 1999-04-21 | 2004-03-26 | Powderject Vaccines Inc | Nucleic acid immunization |
| EP1372704B1 (en) | 2001-03-30 | 2008-10-15 | Ghc Research Development Corporation | Monocyte-specific particulate delivery vehicle |
| WO2003004620A2 (en) | 2001-07-05 | 2003-01-16 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US11529414B2 (en) | 2020-06-23 | 2022-12-20 | Orbis Health Solutions, Llc | Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same |
-
1996
- 1996-09-27 CA CA002233278A patent/CA2233278A1/en not_active Abandoned
- 1996-09-27 AU AU72515/96A patent/AU716497B2/en not_active Ceased
- 1996-09-27 EP EP96933987A patent/EP0863704A4/en not_active Withdrawn
- 1996-09-27 JP JP9513762A patent/JPH11512724A/ja active Pending
- 1996-09-27 CN CN96198106A patent/CN1201369A/zh active Pending
- 1996-09-27 NZ NZ319891A patent/NZ319891A/xx unknown
- 1996-09-27 KR KR1019980702134A patent/KR19990063672A/ko not_active Application Discontinuation
- 1996-09-27 WO PCT/US1996/015728 patent/WO1997011605A1/en not_active Application Discontinuation
- 1996-09-27 PL PL96325953A patent/PL325953A1/xx unknown
- 1996-09-27 TR TR1998/00573T patent/TR199800573T2/xx unknown
- 1996-09-27 SK SK401-98A patent/SK40198A3/sk unknown
- 1996-09-27 HU HU9802651A patent/HUP9802651A3/hu unknown
- 1996-09-27 CZ CZ98929A patent/CZ92998A3/cs unknown
-
1998
- 1998-03-26 BG BG102355A patent/BG102355A/xx unknown
- 1998-03-26 NO NO981386A patent/NO981386L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO981386D0 (no) | 1998-03-26 |
| NZ319891A (en) | 1999-01-28 |
| NO981386L (no) | 1998-05-28 |
| EP0863704A4 (en) | 2003-09-10 |
| HUP9802651A2 (hu) | 1999-02-01 |
| WO1997011605A1 (en) | 1997-04-03 |
| HUP9802651A3 (en) | 2001-08-28 |
| KR19990063672A (ko) | 1999-07-26 |
| AU7251596A (en) | 1997-04-17 |
| BG102355A (en) | 1999-04-30 |
| CZ92998A3 (cs) | 1998-09-16 |
| SK40198A3 (en) | 1998-11-04 |
| CN1201369A (zh) | 1998-12-09 |
| JPH11512724A (ja) | 1999-11-02 |
| TR199800573T2 (xx) | 1998-07-21 |
| EP0863704A1 (en) | 1998-09-16 |
| PL325953A1 (en) | 1998-08-17 |
| AU716497B2 (en) | 2000-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoshikawa et al. | Nanoparticles built by self-assembly of amphiphilic γ-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells | |
| Chikh et al. | Liposomal delivery of CTL epitopes to dendritic cells | |
| EP1083232B1 (en) | Transfer of mRNA using polycationic compounds | |
| AU2007269245B2 (en) | Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells | |
| US9814682B2 (en) | Vaccination with immuno-isolated cells producing an immunomodulator | |
| US7247310B1 (en) | Tumor vaccines | |
| Kjaergaard et al. | Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine | |
| KR20030061838A (ko) | 면역원성이 불량한 항원의 면역원성을 향상시키는 약제조성물 | |
| EP1660040A1 (en) | In vivo targeting of dendritic cells | |
| Cayeux et al. | Direct and indirect T cell priming by dendritic cell vaccines | |
| KR20070068398A (ko) | 재조합 마이코박테리움의 조합물 및 백신과 같은 생물학적활성제 | |
| CA2233278A1 (en) | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization | |
| US6491925B2 (en) | Compositions and methods for cancer prophylaxis and/or treatment | |
| US8053421B2 (en) | DNA vaccines against tumor growth and methods of use thereof | |
| WO1990011085A1 (en) | Large multivalent immunogen | |
| US7176186B1 (en) | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization | |
| US20040146486A1 (en) | Hybrid vector system for use as a vaccine | |
| Jang et al. | Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity | |
| Wu et al. | Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells | |
| MXPA98002405A (en) | Stimulation of medium immune response in objective cells through genetic immunization in particu | |
| EP1222252A1 (en) | New lymphocytes, a process for preparing the same and their use in therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |